Introduction
The eye has a combination of features that make it ideally suited as a target organ for gene therapy. Significant progress has been made in the understanding of the molecular pathology of ocular disorders. A large number of inherited ocular diseases have been defined at the molecular level; there are approximately 150 retinal disease loci with 90 disease-causing genes identified to date, and a wide range of appropriate animal models available for the development of experimental therapies. The highly compartmentalised anatomy of the eye (Figures 1 and 2 ) facilitates accurate delivery of vector suspensions to specific tissues under direct visualisation using microsurgical techniques. This enables precise targeting of vector at target sites within the globe while
In brief Progress
Recombinant adeno-associated virus vectors offer a range of candidates for retinal gene transfer with contrasting tissue-tropisms and expression kinetics. Lentiviral vectors mediate efficient, sustained expression in the retinal pigment epithelium, the corneal endothelium and the trabecular meshwork. Improvements in non-viral methods of gene transfer have facilitated efficient sustained transgene expression and therapeutic effects in the retina. Intraocular transgene expression may be regulated by pharmacologically inducible expression systems. Proof-of-principal for gene replacement therapy has been demonstrated in several experimental models of inherited retinal degeneration resulting from loss-offunction mutations. The expression of mutant genes causing dominantly inherited retinal degenerations may be suppressed by ribozyme-based strategies or RNA interference. Intraocular gene transfer of therapeutic proteins can modify the severity of complex acquired ocular disorders.
Prospects
RNA interference offers a potentially powerful novel approach for therapeutic gene silencing in dominantly inherited disorders owing to gain-of-function mutations, and for downregulation of pathogenic proteins in acquired disorders. Organ culture of donor cornea offers an attractive opportunity for ex vivo transfection by vectors expressing immuno-modulatory cytokines to prevent subsequent allograft rejection. Clinical trials of gene replacement therapy are planned for individuals with inherited early-onset retinal degeneration owing to defects in the gene encoding the visual cycle protein RPE65. minimising systemic dissemination and the possibility of unwanted systemic effects. Intraocular tissues comprise small but stable populations of cells and may be transduced efficiently and stably by small volumes of vector suspension. Immune responses following intraocular administration of vectors are typically attenuated compared to those following systemic administration; anatomical barriers and a unique immune environment maintain a degree of protection from immune responses directed against vector antigens that might otherwise cause inflammation and limit transgene expression. The eye's unique optical transparency enables non-invasive imaging of ocular tissues in vivo. Visual function is readily quantifiable in terms of both psychophysical and electrophysiological parameters, and the contralateral 'fellow' eye offers an invaluable experimental control.
Recombinant adeno-associated virus vectors offer a range of candidates for retinal gene transfer with contrasting tissue-tropisms and expression kinetics Recombinant adeno-associated virus (rAAV) vectors are increasingly utilised for their ability to mediate efficient transduction of retinal pigment epithelium (RPE), photoreceptor cells and ganglion cells. 1 In large animal models, rAAV vectors mediate stable expression in the retina that is maintained for several years. [2] [3] [4] Transgene expression that is sustained in the long term is a highly attractive feature offering the means to target many life-long retinal disorders following a single administration of vector. The tissue specificity and expression kinetics of rAAV vectors are highly dependent on the vector serotype as well as the anatomical compartment of delivery within the globe. The development of hybrid 'pseudotyped' rAAV vectors, in which a rAAV plasmid is packaged within a capsid derived from AAV of a different serotype, has considerably expanded the available repertoire of AAV vectors. rAAV-2/2 (rAAV-2 plasmid packaged in rAAV-2 capsid)-mediated expression is typically of delayedonset, gradually increasing in efficiency to reach stable levels of expression after 2-4 months. In contrast, rAAV-2/1, AAV-2/5 and AAV-5/5 vectors mediate gene expression of rapid onset, with evidence of expression as early as 3-4 days after vector delivery. Whereas AAV-2/2 and AAV-2/5 transduce both photoreceptors and RPE cells, AAV-2/4 and AAV-4/4 mediate expression that is restricted to the RPE. 4 AAV-5 pseudotyped vectors mediate successful gene replacement in rodent and large animal models of inherited retinal degenerations. 5, 6 The range of pseudotyped rAAV vectors offers an array of candidates from which an appropriate vector might be selected according to a desired expression profile.
Lentiviral vectors mediate efficient, sustained expression in the RPE, the corneal endothelium and the trabecular meshwork Lentivirus-based vectors are attractive candidates for ocular gene transfer because of their ability to transduce non-dividing cell populations stably. Human immunodeficiency virus-1 (HIV-1) and feline immunodeficiency virus (FIV)-based lentiviral vectors efficiently transduce the corneal endothelium and trabecular meshwork following delivery into the anterior chamber, 7, 8 and stably transduce cells of the RPE for at least 2 years following delivery to the subretinal space in rodents. [8] [9] [10] Both HIV-1-based and simian lentiviral vectors are able to mediate therapeutic effects in RPE-based retinal degenerations. 10, 11 Lentivirus-mediated transduction of photoreceptor cells appears to be less predictable than transduction of RPE cells, but is reported to occur under certain circumstances depending on retinal maturity, the promoter sequence used and anatomical barriers. Photo- Figure 1 Schematic diagram of the eye showing its major structures and routes of vector delivery. As the eye is highly compartmentalized, transduction efficiencies of different ocular tissues are dependent on the route of vector administration. Vector suspension can be injected into the anterior chamber, the vitreous cavity or the subretinal space. Subretinal delivery involves injection of vector suspension into the potential space between the neurosensory retina and the retinal pigment epithelium. Subretinal injection results in temporary separation of these layers that reappose spontaneously. Gene therapy progress and prospects:the eye JWB Bainbridge et al receptor transduction is evident following subretinal vector delivery in neonatal rodents when driven by a rhodopsin promoter, but the efficiency of photoreceptor transduction in adults is relatively low. 12 The efficiency of photoreceptor cell transduction in adults can be improved by local retinal trauma and by enzymatic disruption of the inter-photoreceptor matrix, suggesting that anatomical barriers to tissue penetration by vector particles may be a limiting factor. [12] [13] [14] The theoretical risk of recombination-mediated lentiviral replication may be minimized through the use of highly deleted vectors generated by re-coded packaging constructs in a four-plasmid system 15 and through the use of self-inactivating vectors. 16 Vectors based on nonprimate lentiviruses such as FIV, equine infectious anaemia virus and bovine immunodeficiency virus have transduction efficiencies and durations of expression in ocular tissues that are comparable to HIV-based vectors and may provide alternatives with potential safety advantages 8, 9, 15, 16 (reviewed in detail elsewhere 17 ). The potential risk of lentivirus-mediated insertional mutagenesis is significantly lower in the eye than in systemic applications as the ocular cells targeted are relatively few in number and can be stably transduced by a proportionately low number of vector particles. The possibility of insertional mutagenesis may be further minimized by the development of non-integrating vectors; recent findings suggest that integrase-deficient vectors can persist as episomal double-stranded DNA circles that are capable of transducing retinal cells in vitro and may mediate efficient sustained expression in ocular tissues in vivo at levels comparable to that of their integrationproficient counterparts. 18 Improvements in non-viral methods of gene transfer have facilitated efficient sustained transgene expression and therapeutic effects in the retina
The transduction efficiency of non-viral vectors in the retina can be substantially improved by adjunctive electroporation. Following intravitreal injection of plasmid DNA, electroporation results in short-lived but efficient transduction of retinal ganglion cells. This technique is reported to facilitate expression of neurotrophic factors sufficient to prolong cell survival in experimental glaucoma models. 19 Electroporation of plasmid DNA delivered to the subretinal space in neonatal rodents leads to efficient reporter gene expression in photoreceptors, bipolar cells and Muller glial cells that is sustained for at least 50 days. 20 The duration of electroporation-mediated expression can be sustained for more than 4 months in adult RPE when integration into the genome is promoted by cotransfection of phiC31 integrase with a plasmid bearing the attB sequence, a site targeted in phiC31 integrase-mediated recombination. 21 Facilitating targeted integration in this way may additionally reduce the possibility of insertional mutagenesis by limiting the number of potential integration sites. Electroporation can be associated with variable adverse effects on normal ocular structures resulting in inflammation, cataract, retinal degeneration and phthysis; further characterisation and development will be required to minimise such effects before possible clinical application.
Intraocular transgene expression may be regulated by pharmacologically inducible expression systems
The ability to regulate transgene expression is a desirable feature of gene delivery systems that can be facilitated by the design of promoter sequences. Pharmacologically inducible systems offer an attractive strategy to regulate temporally the level of intraocular transgene expression in response to the systemic delivery of an appropriate drug. For example, dose-dependent-expression of a reporter gene can be induced in the retina in vivo by single-vector and dual-vector rapamycin-inducible and tetracycline-inducible AAV vector systems. 22 A dimerizer-inducible expression system reproducibly drives reporter gene expression in the retina of nonhuman primates with dose-responsive inducible expression over a period of 2.5 years. 23 Furthermore, tetracycline-inducible expression of interleukin (IL)-10 by a single-vector rAAV system is able to mediate a therapeutic effect in an experimental model of uveitis. 24 An alternative approach is to design a promoter system that is 'vigilant' in its response to a relevant feature of the local tissue environment. For example, transgene expression can be targeted to sites of retinal ischaemia, temporally and spatially, by the incorporation of a hypoxia-responsive element in the promoter of a rAAV vector. 25 Such a system might facilitate targeting and regulation of the expression of an antiangiogenic protein in gene therapy for ischaemia-induced ocular angiogenesis.
Proof-of-principle for gene replacement therapy has been demonstrated in several experimental models of inherited retinal degeneration resulting from loss-of-function mutations Notable successes have been achieved by gene replacement strategies in models of inherited retinal degenerations owing to loss-of-function mutations in genes encoding proteins that mediate critical functions in photoreceptors or RPE cells. rAAV-mediated gene replacement of peripherin, a membrane glycoprotein essential for the formation and stability of photoreceptor outer segments, restores retinal ultrastructure and function for as long as 14 weeks in the rds mouse. In this model, AAV-mediated gene replacement is not sustained in the long term for reasons that may relate to the timing of intervention or to the regulation of peripherin expression. 26 rAAV-mediated gene replacement of retinitis pigmentosa GTPase regulator interacting protein, a protein anchored in the photoreceptor connecting cilia, restores normal localization of RPGR, preserving photoreceptor cells and retinal function in a model of Leber's congenital amaurosis (LCA). 27 In models of X-linked recessive juvenile retinoschisis, rAAV-2-mediated expression of retinoschisin by photoreceptors and ganglion cells in adult mice results in an improvement in Gene therapy progress and prospects:the eye JWB Bainbridge et al electroretinographic responses but no recovery of retinal structure. 28 Gene replacement at an earlier stage in the degeneration, however, by AAV-5-mediated expression of retinoschisin by photoreceptor cells in young animals results in both functional and structural improvements that are maintained for longer than 1 year. 6 Rescue of retinal degeneration in the Royal College of Surgeons rat by gene replacement of Mertk, an RPE receptor tyrosine kinase responsible for phagocytosis of shed photoreceptor outer segments, has been reported using adenoviral, rAAV-2 or lentiviral vectors, resulting in restoration of phagocytic function and slowing of photoreceptor degeneration. 10, 29 Lentivirus-mediated gene replacement in this model results in the most effective rescue with improved retinal function maintained for as long as 6 months, an effect that may reflect the RPE-specific tropism and rapid-onset expression of this vector. 10 In a murine model of ocular albinism, gene replacement of OA1, which encodes a protein responsible for organization of RPE melansomes, is reported to increase melanosome numbers and, unexpectedly, to improve electroretinographic abnormalities, suggesting that gene therapy may offer some improvement in visual function in this disorder which is characterised by prominent developmental abnormalities. 30 LCA is a group of severe early-onset retinal dystrophies. Gene therapy has been described in both rodents and large animal models for one form of LCA that is due to a defect in the gene encoding RPE65, an RPE-specific visual cycle isomerase essential for the synthesis of 11-cis-retinal. This form of LCA is a particularly attractive candidate for a clinical trial of gene replacement. As affected individuals can have very poor vision but relatively preserved retinal structure, gene replacement offers good prospects for measurable improvements in visual function. Following in utero intraocular vector delivery in RPE65À/À knockout mice, rAAV-mediated expression of RPE65 results in efficient RPE transduction and rescue of photoreceptor degeneration. 31 Several groups have demonstrated proof-of-principle for gene replacement therapy in the Swedish Briard dog, a model that is homozygous for a null mutation in RPE65. The defect in the Briard manifests a phenotype similar to that in humans, with poor vision from early life and severely depressed dark-and light-adapted electroretinographic responses. rAAV-mediated expression of RPE65 in the RPE following subretinal vector delivery results in significantly improved visual function as demonstrated by both electrophysiology and behavioural assessments, 32, 33 and stable improvement in visual function has been maintained in many animals for longer than 3 years. 5 The demonstration of long-term functional improvement following gene-replacement of RPE65 in pre-clinical models has supported proposals for clinical trials of rAAV-mediated gene therapy for patients with LCA. Ethical approval has been granted by the National Institutes of Health Recombinant DNA Advisory Committee (RAC) for two proposed trials in the US and by the Gene Therapy Advisory Committee (GTAC) for a trial in the UK.
Recent reports describe correction of the ocular phenotype associated with systemic lysosomal storage diseases by ocular gene replacement therapy. In a model of mucopolysaccharidosis (MPS) VI, rAAV-mediated gene replacement of 4-sulfatase reduces accumulation of dermatan sulfate in RPE cells. In MPS VII, gene replacement of the lysosomal enzyme beta-glucuronidase reduces the accumulation of partially degraded glycosaminoglycans in RPE cells and is reported to result in an improvement in retinal electroretinographic responses. 34 The findings suggest that direct intravitreal gene therapy may provide therapeutic benefits for the retinal disease associated with some lysosomal storage diseases and may additionally result in anterograde transport of the lysosomal enzyme through the optic nerve with a subsequent reduction of lysosomal storage in regions of the brain.
The expression of mutant genes causing dominantly inherited retinal degenerations may be suppressed by ribozyme-based strategies or RNA interference
Ribozyme-based strategies specifically cleave mutant mRNAs, while sparing the wild-type molecule. The development of an individualised ribozyme for each mutation may not be feasible for heterogenous diseases such as retinitis pigmentosa; over 100 different mutations have been described for the rhodopsin gene alone (www.sph.uth.tmc.edu/RetNet/disease.htm; www. retinainternational.org/sci-news/rhomut.htm). An alternative approach, however, may be to use a nonspecific ribozyme that cleaves all the rhodopsin mRNAs (including wild-type as well as mutant rhodopsin mRNAs) by targeting a commonly accessible site, in combination with gene replacement of a wild-type rhodopsin designed to be resistant to the ribozyme. 35 More recently, the potential of RNA interference (RNAi) for silencing expression of mutant genes has attracted wide interest as an alternative strategy for the treatment of dominantly inherited disorders. The application of RNAi strategies to retinal degeneration has yet to be described, but expression of specific short interfering RNAs (siRNAs) in the retina is reported to knockdown expression of transcription factors 20 reducing axotomy-induced apoptosis of ganglion cells. 36 An important challenge for RNAi-based therapy is the development of an effective means of delivering siRNAs to the target cell population. Maintaining therapeutic levels in the eye is likely to require either repeated administration of synthetic siRNAs or vector-mediated expression of short hairpin RNAs. Further concerns that will need to be addressed include the possibilities of off-target nonspecific responses and of a significant interferon response in vivo.
Intraocular gene transfer of therapeutic proteins can modify the severity of complex acquired ocular disorders
Although gene replacement and gene silencing strategies offer exciting prospects for the treatment of specific inherited retinal disorders, other disorders may be less amenable to these corrective approaches. These conditions include, in particular, those associated with abnormal retinal development and those in which retinal Gene therapy progress and prospects:the eye JWB Bainbridge et al degeneration is advanced at birth. Furthermore, the development of individualised corrective gene therapy strategies for patients with disorders due to very rare mutations may be unfeasible. However, generic gene therapy strategies that aim not to correct the gene defect but to ameliorate its consequences offer the possibility of therapies that are widely applicable across a range of conditions. These approaches include the local expression of neurotrophic and antiapoptotic proteins with the aim of promoting cell survival. rAAV-mediated gene delivery of neurotrophic factors is reported to prolong photoreceptor survival in experimental models of retinal degeneration. Such factors include fibroblast-growth factor, glial-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF). GDNF-induced rescue is accompanied by a significant improvement in retinal function. Furthermore, expression of GDNF in combination with gene replacement therapy augments the morphological and functional improvement mediated by gene replacement alone. 37 CNTF-induced preservation of photoreceptors, however, appears to be associated with a paradoxical adverse effect on electroretinographic responses, an effect that may be a result of photoreceptor de-differentiation. 38 The potential reversibility of this effect and its implications for visual function in the long term are yet to be defined.
Gene transfer offers a potentially powerful technique for the targeted sustained local delivery of therapeutic proteins in the management of common complex acquired disorders of the eye including neovascularisation, intraocular inflammation, glaucoma and corneal allograft rejection. Experimental retinal and choroidal neovascularisation can be inhibited by adenovirusmediated or rAAV-mediated expression of vascular endothelial growth factor (VEGF) inhibitors, [39] [40] [41] angiostatin 42 or endostatin. Adenovirus-mediated overexpression of pigment epithelium-derived factor (PEDF) inhibits retinal and choroidal neovascularisation, and furthermore, is reported to induce regression of established new vessels. The results of experimental studies have led to the development of a phase 1 clinical trial of adenovirus-mediated PEDF expression by intravitreal vector delivery in individuals with neovascular agerelated macular degeneration. This clinical trial is currently ongoing and early reports suggest that the vector injections are generally well tolerated. Inhibition of choroidal neovascularisation by gene therapy may not necessitate delivery of vector intraocularly; peri-ocular injection of adenovirus vector results in transduction of peri-ocular tissues with increased levels of PEDF in the choroid and significant inhibition of choroidal neovascularisation in both rodents and large animals. 43, 44 RNAi strategies have been employed to knockdown expression of either VEGF itself 45 or its receptor VEGFR1. 46 Following encouraging results in experimental models, these strategies have been extended to phase 1 clinical trials in which synthetic siRNAs targeting mRNAs of VEGF or VEGFR1 are delivered by repeated intravitreal injections in patients with neovascular agerelated macular degeneration. The duration of knockdown following a single intravitreal injection of siRNAs has yet to be clearly defined, but vector-mediated expression of short 'hairpin' RNAs may offer an effective alternative to repeated intravitreal injections of synthetic siRNAs in the long term.
The severity of experimental autoimmune uveoretinitis (EAU) can be reduced by adenovirus-mediated expression of the immuno-modulatory molecule IL-10 following intravenous, periocular or intravitreal delivery of vector. The brief duration of intraocular transgene expression following injection of the recombinant adenoviral vector can be prolonged by intravitreal transfer of syngeneic retinal Muller glial cells that have been transfected by the same vector ex vivo. 47 rAAV-2-mediated expression of IL-10 significantly decreases disease severity of EAU without affecting splenocyte proliferative responses or serum antibody levels, illustrating the potential of gene therapy strategies to modulate immune responses in local microenvironments without unwanted systemic effects. 48 Expression of CNTF or GDNF by adenoviral and lentiviral vectors prolong retinal ganglion cell survival following axonal injury. 49 rAAV-mediated expression of brain-derived neurotrophic factor (BDNF), enhanced by the incorporation of the woodchuck hepatitis posttranscriptional regulatory element, is of rapid-onset and high efficiency in retinal ganglion cells, leading to significant retinal ganglion cell survival in experimental glaucoma. 50 Expression of BDNF in combination with its receptor, tyrosine receptor kinase B (TrkB), which is normally downregulated after axonal injury, can produce a twofold increase in retinal ganglion cell survival compared with expression of BDNF alone. rAAVmediated expression of extracellular signal-regulated kinase (Erk1/2) has been used to target the intracellular events mediating retinal ganglion cell survival following TrkB activation. 51 Protection of retinal ganglion cells against apoptotic cell death has also been described by rAAV-mediated expression of caspase inhibitors in experimental glaucoma.
Ex vivo gene delivery to the cornea offers an attractive opportunity to modulate corneal allografts rejection. Although the anatomical accessibility of the cornea lends itself to the use of non-viral methods such as electroporation and 'gene gun' technology, these techniques result in low efficiencies of transduction and limited duration of transgene expression compared with adenoviral and lentiviral vectors. 52 The ex vivo transfection of corneal donor tissue before allograft transplantation offers a valuable opportunity to prevent immune rejection by modulating immune responses. Allograft survival can be prolonged by adenovirus-mediated expression of CTLA-Ig, a molecule that disrupts the interaction of T cells with major histocompatibility complex molecules on antigen presenting cells. The extent of corneal stromal haze, a common complication of excimer laser refractive surgery that is believed to result from the uncontrolled proliferation of keratocytes, can be reduced by retrovirus-mediated expression of a dominant-negative mutant cyclin G1 that inhibits the function of its normal counterpart cyclin G1 which is a survival factor for proliferating cells.
Prospects for ocular gene therapy
Gene-based therapies present the means to correct gene defects in inherited ocular disorders by gene replacement or silencing, and offer broad potential applications as a sophisticated system for the targeted, sustained and Gene therapy progress and prospects:the eye JWB Bainbridge et al regulated delivery of therapeutic proteins in a range of acquired ocular disorders. Numerous studies in recent years have demonstrated proof-of-principle that genebased therapies can mediate significant quantifiable improvements in ocular morphology and visual function in experimental and preclinical models. These recent advances have enabled the development of proposals for clinical trials of gene therapies for both inherited and acquired ocular disease. The first results of these trials are awaited with anticipation.
